Expression Profiles of Circulating Cytokines, Chemokines, and Immune Cells in Patients With Hepatitis B Virus Infection

Authors Information
Article Notes and Dates
To Cite : Qi Lian J, Fei Yang X, Rong Zhao R, Yan Zhao Y, Li Y, et al. Expression Profiles of Circulating Cytokines, Chemokines, and Immune Cells in Patients With Hepatitis B Virus Infection, Hepat Mon. 2014 ;14(6):e18892. doi: 10.5812/hepatmon.18892.
Copyright: Copyright © 2014, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Lok AS, McMahon BJ, Practice Guidelines Committee AAFTSOLD. Chronic hepatitis B. Hepatology. 2001; 34(6): 1225-41[DOI][PubMed]
  • 2. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3): 661-2[DOI][PubMed]
  • 3. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6(3): 531-61[DOI]
  • 4. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol. 2011; 26(4): 628-38[DOI][PubMed]
  • 5. Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol. 2006; 87: 1439-49[DOI][PubMed]
  • 6. Hui CK, Lau GK. Immune system and hepatitis B virus infection. J Clin Virol. 2005; 34 Suppl 1-8[PubMed]
  • 7. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009; 29 Suppl 1: 100-7[DOI][PubMed]
  • 8. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004; 350(11): 1118-29[DOI][PubMed]
  • 9. Hui CK, Leung N, Yuen ST, Zhang HY, Leung KW, Lu L, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 2007; 46(2): 395-401[DOI][PubMed]
  • 10. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007; 47(6): 760-7[DOI][PubMed]
  • 11. Zhang Y, Lian JQ, Li Y, Wang JP, Huang CX, Bai XF, et al. Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine. Eur J Gastroenterol Hepatol. 2013; 25(7): 814-9[DOI][PubMed]
  • 12. Zhang Y, Cobleigh MA, Lian JQ, Huang CX, Booth CJ, Bai XF, et al. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology. 2011; 141(5): 1897-906[DOI][PubMed]
  • 13. He D, Li M, Guo S, Zhu P, Huang H, Yan G, et al. Expression pattern of serum cytokines in hepatitis B virus infected patients with persistently normal alanine aminotransferase levels. J Clin Immunol. 2013; 33(7): 1240-9[DOI][PubMed]
  • 14. Garabedian L, Struyf S, Opdenakker G, Sozzani S, Van Damme J, Laureys G. Langerhans cell histiocytosis: a cytokine/chemokine-mediated disorder? Eur Cytokine Netw. 2011; 22(3): 148-53[DOI][PubMed]
  • 15. Kakimi K, Lane TE, Wieland S, Asensio VC, Campbell IL, Chisari FV, et al. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med. 2001; 194(12): 1755-66[PubMed]
  • 16. Li S, Cai C, Feng J, Li X, Wang Y, Yang J, et al. Peripheral T lymphocyte subset imbalances in children with enterovirus 71-induced hand, foot and mouth disease. Virus Res. 2014; 180: 84-91[DOI][PubMed]
  • 17. Zeng M, Zheng X, Wei R, Zhang N, Zhu K, Xu B, et al. The cytokine and chemokine profiles in patients with hand, foot and mouth disease of different severities in Shanghai, China, 2010. PLoS Negl Trop Dis. 2013; 7(12)[DOI][PubMed]
  • 18. Muller M, Carter S, Hofer MJ, Campbell IL. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum. Neuropathol Appl Neurobiol. 2010; 36(5): 368-87[DOI][PubMed]
  • 19. Wang J, Nikrad MP, Phang T, Gao B, Alford T, Ito Y, et al. Innate immune response to influenza A virus in differentiated human alveolar type II cells. Am J Respir Cell Mol Biol. 2011; 45(3): 582-91[DOI][PubMed]
  • 20. Weigt SS, Derhovanessian A, Liao E, Hu S, Gregson AL, Kubak BM, et al. CXCR3 chemokine ligands during respiratory viral infections predict lung allograft dysfunction. Am J Transplant. 2012; 12(2): 477-84[DOI][PubMed]
  • 21. Park JW, Li Z, Choi JS, Oh HJ, Park SH, Yoon KC. Expression of CXCL9, -10, and -11 in the aqueous humor of patients with herpetic endotheliitis. Cornea. 2012; 31(11): 1246-50[DOI][PubMed]
  • 22. Sellner J, Dvorak F, Zhou Y, Haas J, Kehm R, Wildemann B, et al. Acute and long-term alteration of chemokine mRNA expression after anti-viral and anti-inflammatory treatment in herpes simplex virus encephalitis. Neurosci Lett. 2005; 374(3): 197-202[DOI][PubMed]
  • 23. Zeremski M, Dimova R, Brown Q, Jacobson IM, Markatou M, Talal AH. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis. 2009; 200(11): 1774-80[DOI][PubMed]
  • 24. Berres ML, Trautwein C, Schmeding M, Eurich D, Tacke F, Bahra M, et al. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection. Hepatology. 2011; 53(2): 596-603[DOI][PubMed]
  • 25. Xiang X, Gui H, King NJ, Cole L, Wang H, Xie Q, et al. IL-22 and non-ELR-CXC chemokine expression in chronic hepatitis B virus-infected liver. Immunol Cell Biol. 2012; 90(6): 611-9[DOI][PubMed]
  • 26. Okuhara S, Umemura T, Joshita S, Shibata S, Kimura T, Morita S, et al. Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B. Hepatol Res. 2013; [DOI][PubMed]
  • 27. Zeremski M, Hooker G, Shu MA, Winkelstein E, Brown Q, Des Jarlais DC, et al. Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol. 2011; 55(3): 545-53[DOI][PubMed]
  • 28. Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M, et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology. 2008; 48(5): 1440-50[DOI][PubMed]
  • 29. Dezerega A, Pozo P, Hernandez M, Oyarzun A, Rivera O, Dutzan N, et al. Chemokine monocyte chemoattractant protein-3 in progressive periodontal lesions in patients with chronic periodontitis. J Periodontol. 2010; 81(2): 267-76[DOI][PubMed]
  • 30. Qiu Y, Zeltzer S, Zhang Y, Wang F, Chen GH, Dayrit J, et al. Early induction of CCL7 downstream of TLR9 signaling promotes the development of robust immunity to cryptococcal infection. J Immunol. 2012; 188(8): 3940-8[DOI][PubMed]
  • 31. Modi WS, Goedert JJ, Strathdee S, Buchbinder S, Detels R, Donfield S, et al. MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission. AIDS. 2003; 17(16): 2357-65[DOI][PubMed]
  • 32. Greco G, Mackewicz C, Levy JA. Sensitivity of human immunodeficiency virus infection to various alpha, beta and gamma chemokines. J Gen Virol. 1999; 80 ( Pt 9): 2369-73[PubMed]
  • 33. Renner NA, Ivey NS, Redmann RK, Lackner AA, MacLean AG. MCP-3/CCL7 production by astrocytes: implications for SIV neuroinvasion and AIDS encephalitis. J Neurovirol. 2011; 17(2): 146-52[DOI][PubMed]
  • 34. Xing TJ, Xu HT, Xian JC, Shen ML, Li H, Ye J, et al. Mechanism and efficacy of mobilization of granulocyte colony-stimulating factor in the treatment of chronic hepatic failure. Hepatogastroenterology. 2013; 60(121): 170-5[DOI][PubMed]
  • 35. Duan XZ, Liu FF, Tong JJ, Yang HZ, Chen J, Liu XY, et al. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol. 2013; 19(7): 1104-10[DOI][PubMed]
  • 36. Lv W, Duan Q, Wang L, Gong Z, Yang F, Song Y. Gene expression levels of cytokines in peripheral blood mononuclear cells from patients with pulmonary embolism. Mol Med Rep. 2013; 7(4): 1245-50[DOI][PubMed]
  • 37. Zhang Y, Lian JQ, Huang CX, Wang JP, Wei X, Nan XP, et al. Overexpression of Toll-like receptor 2/4 on monocytes modulates the activities of CD4(+)CD25(+) regulatory T cells in chronic hepatitis B virus infection. Virology. 2010; 397(1): 34-42[DOI][PubMed]
  • 38. Nan XP, Zhang Y, Yu HT, Li Y, Sun RL, Wang JP, et al. Circulating CD4+CD25high regulatory T cells and expression of PD-1 and BTLA on CD4+ T cells in patients with chronic hepatitis B virus infection. Viral Immunol. 2010; 23(1): 63-70[DOI][PubMed]
  • 39. Kryczek I, Wei S, Zou L, Zhu G, Mottram P, Xu H, et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol. 2006; 177(1): 40-4[PubMed]
  • 40. Barboza L, Salmen S, Goncalves L, Colmenares M, Peterson D, Montes H, et al. Antigen-induced regulatory T cells in HBV chronically infected patients. Virology. 2007; 368(1): 41-9[DOI][PubMed]
  • 41. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991; 174(5): 1209-20[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check